Analysis Points to Declining Returns on R&D for Pharmaceutical Companies

Source: Deloitte

The pharmaceutical industry continues to face an extremely challenging R&D environment and has yet to turn a corner in terms of its R&D value proposition, according to a new study released by Deloitte. Despite this, the report presents an optimistic road ahead for R&D and business leaders, exploring the emerging technologies that have the potential to dramatically transform the productivity and efficiency by which drugs are discovered, developed and brought to patients.

The eighth annual pharmaceutical innovation study by the Deloitte Centre for Health Solutions looks at the state of R&D in the biopharma industry and estimates the return on investment that 12 large cap biopharma companies may expect to achieve. The report also includes an extension cohort of four mid-tier biopharma companies.

Read the full report here.

Related Content